All articles by Divya Tirumalaraju
Divya Tirumalaraju
Lilly’s Covid-19 antibody combo EUA expands for post-exposure prophylaxis
The authorisation comes after the US Government resumed the supply of bamlanivimab and etesevimab together.
Biocon Biologics enters strategic collaboration with Serum Institute unit
Biocon Biologics will offer a nearly 15% stake to SILS and will gain access to 100 million vaccine doses.
Health Canada grants full approval to Moderna and Pfizer Covid-19 shots
Both vaccines received Canadian authorisation under an Interim Order in December last year.
BioMarin’s Voxzogo receives EC approval for achondroplasia in children
Voxzogo, which acts on achondroplasia’s underlying pathophysiology, is the first to get approval for this indication in Europe.
Roche to withdraw Tecentriq for one breast cancer indication in US
Based on changes in the mTNBC therapy landscape, FDA does not consider it suitable to continue this indication for Tecentriq.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Pfizer secures provisional approval for Covid-19 vaccine in Australia
Comirnaty is the first Covid-19 vaccine to obtain regulatory approval in Australia, following first full approval by the US FDA.
Amgen to build new $365m manufacturing plant in Ohio, US
With construction planned to commence this year, the new plant will become operational by 2024.
STADA to acquire 16 consumer healthcare brands from Sanofi
The transaction does not cover manufacturing assets and employees related to the brands.
RedHill Biopharma’s opaganib shows activity against Covid-19 variants
The preclinical study assessed the drug’s in vitro effectiveness in blocking the Beta and Gamma SARS-CoV-2 variants.
EC approves Chugai’s Enspryng for NMOSD treatment
The drug, designed using Chugai’s recycling antibody technology, is approved in 54 countries.